These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33176459)

  • 1. Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions.
    Rao BR; Dickert NW; Morris AA; Speight CD; Smith GH; Shore S; Moore MA
    Circ Heart Fail; 2020 Nov; 13(11):e007094. PubMed ID: 33176459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discussing Out-of-Pocket Costs With Patients: Shared Decision Making for Sacubitril-Valsartan in Heart Failure.
    Smith GH; Shore S; Allen LA; Markham DW; Mitchell AR; Moore M; Morris AA; Speight CD; Dickert NW
    J Am Heart Assoc; 2019 Jan; 8(1):e010635. PubMed ID: 30592239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Show Me the Money: Patients' Perspectives on a Decision Aid for Sacubitril/Valsartan Addressing Out-of-Pocket Cost.
    Dickert NW; Mitchell AR; Venechuk GE; Matlock DD; Moore MA; Morris AA; Pierce KJ; Speight CD; Allen LA
    Circ Cardiovasc Qual Outcomes; 2020 Dec; 13(12):e007070. PubMed ID: 33302715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan.
    Venechuk GE; Allen LA; Doermann Byrd K; Dickert N; Matlock DD
    Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006255. PubMed ID: 32814457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
    McMurray JJV; Trueman D; Hancock E; Cowie MR; Briggs A; Taylor M; Mumby-Croft J; Woodcock F; Lacey M; Haroun R; Deschaseaux C
    Heart; 2018 Jun; 104(12):1006-1013. PubMed ID: 29269379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis.
    Zacà V
    J Cardiovasc Med (Hagerstown); 2018 Oct; 19(10):597-605. PubMed ID: 30160656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What will be the impact of sacubitril/valsartan in clinical practice?
    Metra M
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e88-e90. PubMed ID: 29084021
    [No Abstract]   [Full Text] [Related]  

  • 8. Integrating Cost into Shared Decision-Making for Heart Failure with Reduced Ejection Fraction (POCKET-COST-HF): A Trial Providing Out-of-Pocket Costs for Heart Failure Medications during Clinical Encounters.
    Montembeau SC; Rao BR; Mitchell AR; Speight CD; Allen LA; Halpern SD; Ko YA; Matlock DD; Moore MA; Morris AA; Scherer LD; Ubel P; Dickert NW
    Am Heart J; 2024 Mar; 269():84-93. PubMed ID: 38096946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.
    Ramos IC; Versteegh MM; de Boer RA; Koenders JMA; Linssen GCM; Meeder JG; Rutten-van Mölken MPMH
    Value Health; 2017 Dec; 20(10):1260-1269. PubMed ID: 29241885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Costs and Caution Yield Slow Start for New Heart Drugs.
    Kuehn BM
    Circulation; 2018 Jan; 137(2):197-199. PubMed ID: 29311350
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States.
    Zueger PM; Kumar VM; Harrington RL; Rigoni GC; Atwood A; DiDomenico RJ; Touchette DR
    Pharmacotherapy; 2018 May; 38(5):520-530. PubMed ID: 29601093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD
    JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
    King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
    JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea.
    Park SK; Hong SH; Kim H; Kim S; Lee EK
    Clin Ther; 2019 Jun; 41(6):1066-1079. PubMed ID: 31101372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D.
    DeJong C; Kazi DS; Dudley RA; Chen R; Tseng CW
    JAMA Cardiol; 2019 Aug; 4(8):828-830. PubMed ID: 31290933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand.
    Krittayaphong R; Permsuwan U
    Am J Cardiovasc Drugs; 2018 Oct; 18(5):405-413. PubMed ID: 29926351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
    Liang L; Bin-Chia Wu D; Aziz MIA; Wong R; Sim D; Leong KTG; Wei YQ; Tan D; Ng K
    J Med Econ; 2018 Feb; 21(2):174-181. PubMed ID: 28959905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction.
    Gaziano TA; Fonarow GC; Velazquez EJ; Morrow DA; Braunwald E; Solomon SD
    JAMA Cardiol; 2020 Nov; 5(11):1236-1244. PubMed ID: 32785628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands.
    van der Pol S; Degener F; Postma MJ; Vemer P
    Value Health; 2017 Mar; 20(3):388-396. PubMed ID: 28292483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany.
    Gandjour A; Ostwald DA
    Pharmacoeconomics; 2018 Oct; 36(10):1285-1296. PubMed ID: 30054868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.